Vera Therapeutics (VERA) Research & Development (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Research & Development data on file, last reported at $86.0 million in Q1 2026.

• Quarterly Research & Development rose 108.37% year-over-year to $86.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $260.0 million (up 80.24% YoY) and the FY2025 annual result came in at $215.3 million, up 70.61% from the prior year.
• Research & Development climbed to $86.0 million in Q1 2026, from $59.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $86.0 million in Q1 2026 to a low of $3.7 million in Q3 2022.
• A 5-year average of $35.1 million and a median of $29.3 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 2490.81% — and 2023, when it slumped 68.17%.
• Tracing VERA's Research & Development over 5 years: stood at $65.3 million in 2022, then tumbled by 68.17% to $20.8 million in 2023, then soared by 60.44% to $33.3 million in 2024, then jumped by 77.86% to $59.3 million in 2025, then soared by 45.02% to $86.0 million in 2026.
• The last three Research & Development figures came in at $86.0 million (Q1 2026), $59.3 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.